Institut für Transfusionsmedizin, Universität Ulm und Institut für Klinische Transfusionsmedizin und Immungenetik Ulm, DRK-Blutspendedienst Baden-Württemberg-Hessen, Germany.
Cytotherapy. 2012 May;14(5):540-54. doi: 10.3109/14653249.2012.655420. Epub 2012 Feb 2.
The clinical use of human mesenchymal stromal cells (MSC) requires ex vivo expansion in media containing supplements such as fetal bovine serum or, alternatively, human platelet lysate (PL).
Platelet concentrates were frozen, quarantine stored, thawed and sterile filtered to obtain PL. PL content and its effect on fibroblast-colony-forming unit (CFU-F) formation, MSC proliferation and large-scale expansion were studied.
PL contained high levels of basic fibroblast growth factor (bFGF), soluble CD40L (sCD40L), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), platelet-derived growth factor AA (PDGF-AA), platelet-derived growth factor AB/BB (PDGF-AB/BB), chemokine (C-C) ligand 5 (CCL5; RANTES) transforming growth factor-β1 (TGF-β1) and chemokine (C-X-C) ligand 1/2/3 (GRO), with low batch-to-batch variability, and most were stable for up to 14 days. Inhibition of PDGF-BB and bFGF decreased MSC proliferation by about 20% and 50%, respectively. The strongest inhibition (about 75%) was observed with a combination of anti-bFGF + anti-PDGF-BB and anti-bFGF + anti-TGF-β1 + anti-PDGF-BB. Interestingly, various combinations of recombinant PDGF-BB, bFGF and TGF-β1 were not sufficient to promote cell proliferation. PL from whole blood-derived pooled platelet concentrates and apheresis platelet concentrates did not differ significantly in their growth-promoting activity on MSC.
PL enhances MSC proliferation and can be regarded as a safe tool for MSC expansion for clinical purposes. \in particular, PDGF-BB and bFGF are essential components for the growth-promoting effect of PL, but are not sufficient for MSC proliferation.
临床使用人间质基质细胞(MSC)需要在含有胎牛血清或人血小板裂解液(PL)等补充剂的培养基中进行体外扩增。
将血小板浓缩物冷冻、检疫储存、解冻并无菌过滤以获得 PL。研究了 PL 的含量及其对成纤维细胞集落形成单位(CFU-F)形成、MSC 增殖和大规模扩增的影响。
PL 含有高水平的碱性成纤维细胞生长因子(bFGF)、可溶性 CD40L(sCD40L)、血管细胞黏附分子-1(VCAM-1)、细胞间黏附分子-1(ICAM-1)、血小板衍生生长因子 AA(PDGF-AA)、血小板衍生生长因子 AB/BB(PDGF-AB/BB)、趋化因子(C-C)配体 5(CCL5;RANTES)、转化生长因子-β1(TGF-β1)和趋化因子(C-X-C)配体 1/2/3(GRO),批间变异性低,其中大多数在 14 天内稳定。PDGF-BB 和 bFGF 抑制分别使 MSC 增殖减少约 20%和 50%。用抗-bFGF+抗-PDGF-BB 和抗-bFGF+抗-TGF-β1+抗-PDGF-BB 的组合观察到最强的抑制作用(约 75%)。有趣的是,重组 PDGF-BB、bFGF 和 TGF-β1 的各种组合不足以促进细胞增殖。来源于全血来源的汇集血小板浓缩物和单采血小板浓缩物的 PL 在促进 MSC 增殖方面没有显著差异。
PL 增强了 MSC 的增殖,可以被视为用于临床 MSC 扩增的安全工具。特别是,PDGF-BB 和 bFGF 是 PL 促生长作用的必需成分,但不足以促进 MSC 增殖。